Dendreon Corp (NASDAQ:DNDN)
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
engineer891
(87.21)
Submitted: 12/31/2007 1:44:01 PM :
Start Price:
$6.28
DNDN Score:
+19.60
LAWSUIT WILL CAUSE PROVENGE TO BE APPROVED BY FDA AND STOCK WILL SOAR
Recs
PhDinMS
(29.81)
Submitted: 12/28/2007 6:30:36 PM :
Start Price:
$6.32
DNDN Score:
+18.91
Provenge will be approved by the FDA.
Recs
RockyNicky3728
(31.28)
Submitted: 12/26/2007 6:56:42 PM :
Start Price:
$6.40
DNDN Score:
+18.71
Good growth.
Recs
hightechallthewa
(70.15)
Submitted: 12/20/2007 8:33:58 AM :
Start Price:
$6.35
DNDN Score:
+17.72
Play it right...yes, you heard me right, "Play", not "Invest" when it comes to this DNDN strong comer. Are all of us traders qualified to technically comment on the medical performance of this company's Provenge clinical results? Of course not! But we surely can read them and act accordingly. A smart thing to do is to protect your long position with a "medium length" long Put position (also called a protective put). Use your techinacl analysis interpretations to determine your entry position and timing.
Recs
FundamentalGamma
(56.33)
Submitted: 12/18/2007 12:15:48 AM :
Start Price:
$6.71
DNDN Score:
-11.23
FS = 22
Gamma = .37
Fundamentals bad, price overvalued.
Recs
elmyko1
(< 20)
Submitted: 12/17/2007 12:05:20 AM :
Start Price:
$7.06
DNDN Score:
+6.31
Its a gamble but hey if congress is starting a probe cause everyone is complaining cause they want the drug ok'ed then this might give us a nice run and we should try and make some money on it
Recs
Jorgedig
(27.87)
Submitted: 11/12/2007 12:43:29 PM :
Start Price:
$6.84
DNDN Score:
+9.44
I'm betting on FDA approval for Provenge once the efficacy phase is completed. I also like the small molecules and molecular antibodies in the distant pipeline as well as the breast/ovarian/colon cancer immunotherapy product.
Recs
kevrose31
(57.46)
Submitted: 11/3/2007 5:54:49 PM :
Start Price:
$7.25
DNDN Score:
+5.58
Just wait for the spike and BAM!
Recs
rpmf08
(53.81)
Submitted: 10/24/2007 3:29:00 PM :
Start Price:
$7.56
DNDN Score:
+2.24
medical companys... gotta love the volatility!
i think there prostate cancer project will go through and go to around 14 a share.
Recs
hetrevillion
(20.36)
Submitted: 10/3/2007 1:25:42 AM :
Start Price:
$7.75
DNDN Score:
-1.76
slow drift down until new drug is approved.
Recs
Afthought
(31.36)
Submitted: 9/21/2007 3:25:21 PM :
Start Price:
$8.06
DNDN Score:
-2.49
Tick, tick, tick
Recs
downbytheriver1
(< 20)
Submitted: 9/18/2007 5:06:22 PM :
Start Price:
$8.12
DNDN Score:
-3.08
unique biotech
Recs
latimerburned
(92.85)
Submitted: 9/14/2007 4:09:23 PM :
Start Price:
$7.98
DNDN Score:
-4.66
If provenge is approved this will be a big winner, if not then it will underperform for a long time. I like the risk reward.
Recs
idratherbeontour
(23.52)
Submitted: 9/11/2007 11:53:58 AM :
Start Price:
$8.25
DNDN Score:
-8.69
fast money 'Pete Najarian likes Dendreon (DNDN) on recent options activity."
Recs
polo1000
(55.24)
Submitted: 8/27/2007 1:14:30 PM :
Start Price:
$8.26
DNDN Score:
-8.14
once the trials are complete, the name will attract investors. this new direction in pharmacuticles will yeild a new boon.
Recs
southpoledave
(< 20)
Submitted: 8/18/2007 10:54:51 PM :
Start Price:
$8.03
DNDN Score:
-7.25
The recent news release will boost the shares.
Recs
orientalavenue
(< 20)
Submitted: 8/17/2007 4:28:59 PM :
Start Price:
$8.03
DNDN Score:
-7.25
FDA loses.................
Recs
tharlow
(31.04)
Submitted: 8/14/2007 12:36:47 AM :
Start Price:
$7.33
DNDN Score:
-1.55
The ultimate placebo. Sugar tablets have never been so high-tech.
Recs
Belzipy
(87.96)
Submitted: 8/9/2007 5:57:07 PM :
Start Price:
$7.14
DNDN Score:
+3.27
Looks like a good long term. So cheap, doesn't really matter.
Recs
StwPer
(43.58)
Submitted: 8/1/2007 4:37:05 AM :
Start Price:
$7.51
DNDN Score:
-1.11
A non-profit, Ohio based, patient advocacy group, "Care to Live" is sueing the FDA over stonewalling the approval of the prostate cancer drug, Provenge. Care to Live intends to prove the FDA's motives are a political ploy, among other things. See more at: http://seattletimes.nwsource.com/html/businesstechnology/2003813806_dendreon31.html
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 161 - 180 of 347 : « Previous 4 5 6 7 8 9 10 11 12 13 Next »